Search

everythinglearnresearchcommunity

for

Search:↓

A 43-year-old noticed significant hair thinning and is using topical minoxidil, dermarolling, Alpecin, biotin, zinc, copper, vitamin D, and rosemary oil. They plan to see an endocrinologist and have blood tests scheduled to investigate further.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Topical finasteride concentrations are likely much higher than necessary for effective follicular DHT suppression, with current standards being 100-1000 times above the theoretical minimum. Lower concentrations (0.001-0.0025%) might still work locally while minimizing systemic exposure.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Exosomes are discussed as a new hair loss treatment, but skepticism is expressed about their effectiveness. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.

Oral minoxidil can cause serious heart issues like cardiac hypertrophy and arrhythmias, prompting some users to reduce dosage or switch to topical treatments. Despite significant hair regrowth, side effects such as shortness of breath and chest pains are common concerns.

A 23-year-old male has been using oral dutasteride and minoxidil for 1.5 years for temple recession, adding topical minoxidil and tretinoin 5-6 months ago, and recently adjusted thyroid medication and added iron supplements due to deficiencies. He noticed some baby hairs but no significant growth yet, and reports no shedding on dutasteride.

Dutasteride is more effective than finasteride, has neuroprotective benefits, and may prevent acne. Despite initial concerns about metabolic effects, further research suggests it is safe for most users, especially if not hypogonadal.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The user has been experiencing hair thinning despite taking finasteride and minoxidil for six months. Bloodwork suggests a vitamin D deficiency, and users recommend consulting a doctor and possibly supplementing vitamin D.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

A 23-year-old man with hair loss, despite using dutasteride, oral minoxidil, and RU58841, is considering bicalutamide for regrowth but is concerned about feminization. Alternatives like topical estrogen, JXL069, and spironolactone are discussed, with suggestions to explore thyroid levels and other potential underlying conditions.

A 25-year-old male experienced increased testosterone and estradiol levels after starting finasteride for hair loss, leading his doctor to suggest a testicular ultrasound as a precaution. The user questions the necessity of the ultrasound, considering it potentially excessive, while others suggest it could be a useful precaution to rule out any issues.

The user is considering using Ruderma to maintain hair and is concerned about potential hair loss acceleration due to starting TRT. They are also inquiring about the use of minoxidil, RU58841, and a derma roller for hair maintenance.

New hair loss treatments like PP-405, AMP-303, and SCUBE3 are being discussed, but none are confirmed to fully restore hairlines. Current treatments like Minoxidil, Finasteride, and RU58841 are still widely used, with some hope for future advancements in hair regrowth.

User is experiencing hair thinning and sebum overproduction after starting finasteride and a hair growth supplement containing biotin, iron, zinc, and calcium. They suspect the finasteride might be fake but have noticed a side effect of watery semen.

A 20-year-old male experiencing significant hair loss started using finasteride and minoxidil, considering switching to dutasteride, and seeking encouragement from others who have seen improvements. Other users shared their experiences with similar treatments, noting improvements in hair coverage and stability, with some considering hair transplants as a future option.

The conversation is about differing experiences with finasteride for hair loss, with some users reporting side effects and others not, and the debate over the drug's safety and effectiveness. Specific treatments mentioned include finasteride, dutasteride, and topical finasteride.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The user is experiencing one-sided diffuse thinning and has been using finasteride and liquid minoxidil for 4-5 years with minimal results. They are considering whether to save for a hair transplant or address scalp sensitivity and irritation first.

Combining finasteride with dutasteride may have additive benefits for reducing scalp DHT, but the extent is unknown. Some users report less shedding when using both treatments, with variations in dosage and application methods.

Combining finasteride with minoxidil and tretinoin is discussed, with concerns about potential overdose. It is suggested that high doses of finasteride do not provide additional benefits beyond 1 mg.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

Hair loss treatments include finasteride, minoxidil, microneedling, dutasteride, CB-03-01, RU-58841, and experimental options like KY-19382 and stem cell therapy. Some treatments are considered ineffective or risky, such as ketoconazole, PRP, and low-level laser therapy.

A 30-year-old female with telogen effluvium and androgenetic alopecia is using spironolactone, oral minoxidil, vitamin D, iron sulfate, and a hairmax laser band. She seeks recommendations for a dermastamp or derma roller, advised to use no higher than 0.5 mm.

User tried various hair loss treatments, including natural remedies, topical and oral finasteride, RU with stemoxydine, and topical dutasteride. All treatments had side effects, and topical dutasteride thickened hair but also caused side effects.

A 33-year-old experienced significant hair loss after a depressive episode and taking paroxetine, possibly due to telogen effluvium or androgenic alopecia. Suggestions included reducing alcohol, considering finasteride and minoxidil, and consulting a doctor about antidepressant side effects.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.